Microcap Ledger Calidi Biotherapeutics, Inc. $CLDI
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- NYSE American
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- San Diego, CA
- Fiscal year end
- December 31
- Shares outstanding
- 2,584,184 [10-Q 2026-08-13]
What the company doesAI summary of filing
Calidi Biotherapeutics is a pre-revenue biotechnology company developing oncolytic virus-based therapies for cancer treatment. The company has not generated any revenue from product sales and has no approved products on the market. It is developing three main product platforms: RedTail (an enveloped oncolytic virus designed for systemic delivery to metastatic tumors), SuperNova (oncolytic virus delivered via allogeneic stem cells for solid tumors), and NeuroNova (oncolytic virus in neural stem cells for high-grade glioma). The company makes money through potential future product sales and currently plans to file an investigational new drug application for its lead RedTail candidate, CLD-401, by the end of 2026. [10-K 2026-03-27]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$8.27M | −$8.47M | $4.29M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | — | −$19.91M | −$21.29M | $5.82M | [10-K 2026-03-27] |
| FY ended Dec 2024 | — | −$22.14M | −$19.69M | $9.60M | [10-K 2026-03-27] |
- Quarterly cash burn
- −$4.23M
- Cash runway Estimate
- ~3 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-07 | 13,078,022 | [10-Q 2024-11-12] |
| 2025-03-24 | 28,467,580 | [10-K 2025-03-31] |
| 2025-05-09 | 31,792,580 | [10-Q 2025-05-14] |
| 2025-08-04 | 3,426,406 | [10-Q 2025-08-08] |
| 2025-11-10 | 7,167,721 | [10-Q 2025-11-13] |
| 2026-03-20 | 10,895,725 | [10-K 2026-03-27] |
| 2026-05-08 | 19,311,625 | [10-Q 2026-05-14] |
| 2026-08-10 | 2,584,184 | [10-Q 2026-08-13] |
- Shelf registration
- S-1 filed 2025-08-15; declared effective 2025-08-20 [S-1 2025-08-15]
Listing status
Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-09-25. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-09-25 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-09-25] |
| 2024-10-18 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2024-10-18] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-25 | 8-K | Listing notice or transfer; Other events |
| 2026-09-22 | 8-K | Material agreement entered; Other events |
| 2026-09-17 | 424B5 | Prospectus or prospectus supplement |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-13 | 8-K | Results of operations; Regulation FD disclosure |
| 2026-07-31 | 8-K | Change to security holder rights; Charter, bylaws or fiscal year change |
| 2026-07-16 | 8-K | Material agreement entered; Material agreement terminated; New financial obligation |
| 2026-06-23 | 8-K | Director or officer change; Regulation FD disclosure; Other events |
| 2026-06-18 | 8-K | Shareholder vote results |
| 2026-05-29 | 8-K | Material agreement entered; Unregistered sale of equity |
| 2026-05-15 | 13G | Beneficial ownership report (5%+ holder) |
Alerts for $CLDI
Email me when Calidi Biotherapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.